Get started
Author

Mingzhe Xiao

Identification of a cellularly active SIRT6 allosteric activator
2018 · Zhimin Huang, Junxing Zhao, et al. · Nature Chemical Biology · 279
Differences of inflammatory and non-inflammatory indicators in Coronavirus disease-19 (COVID-19) with different severity
2020 · Miao Wang, Qiguo Zhu, et al. · Infection Genetics and Evolution · 29
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
2020 · Xiangyu Su, Jing Zhang, et al. · OncoTargets and Therapy · 20
PDF
PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
2022 · Yiting Dong, Lele Zhao, et al. · Cell Proliferation · 15
PDF
SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway
2022 · Yuting Wang, Jicheng Yue, et al. · Frontiers in Oncology · 14
Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report
2019 · Weiwei Kong, Jia Wei, et al. · OncoTargets and Therapy · 13
PDF
NOTCH1 Mutation Impairs the Adaptive Immune Response, Leading to Decreased Relapse-Free Survival In Patients with Resected T1-2N0 Laryngeal Cancer
2022 · Xiaoyang Gong, Haibin Chen, et al. · Frontiers in Immunology · 12
Reply to: Binding site for MDL-801 on SIRT6
2021 · Zhimin Huang, Junxing Zhao, et al. · Nature Chemical Biology · 9
Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck
2021 · Hai-bing Chen, Xiao-yang Gong, et al. · Oral Oncology · 8
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
2022 · An-guo Chen, Dong-sheng Chen, et al. · Frontiers in Oncology · 7
PDF
Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
2022 · Xiaoyue Zhou, Huajie Dong, et al. · Journal of Clinical Oncology · 6
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
2023 · Shiqi Hu, Yaqin Liu, et al. · Investigational New Drugs · 5
Long non‐coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR‐873‐5p to upregulate PRKAR2
2022 · Qingqi Hong, Peishan Mai, et al. · Environmental Toxicology · 5
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation
2021 · Lin-ling Jin, Zhen-zhen Wu, et al. · Investigational New Drugs · 5
PDF
A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma
2020 · Ye Lv, Feng Ling, et al. · Journal of Thoracic Oncology · 5
PDF
Successful treatment of pulmonary lymphangitic carcinomatosis by anlotinib in 14 Chinese patients with advanced non-small cell lung cancer.
2021 · Shencun Fang, Wanwan Cheng, et al. · Journal of Clinical Oncology · 4
Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib
2020 · Guojiang Zhao, Lin Chen, et al. · Lung Cancer · 4
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC
2020 · Qian Zhang, Ting Jiang, et al. · Journal of Thoracic Oncology · 4
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations
2019 · Wei Heng, Chuanyun You, et al. · Lung Cancer · 4
Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
2022 · Changqing Dong, Wanwan Cheng, et al. · Frontiers in Oncology · 3
Extended neoadjuvant therapy in NSCLC achieved remarkable pathological complete response (pCR) rate and prolonged disease-free survival.
2022 · Zhaohui Fan, Xiaojunn Wang, et al. · Journal of Clinical Oncology · 3
Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report
2021 · Li Zhang, Lin Chen, et al. · Oral Oncology · 3
The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers
2021 · Hui-hui Ma, Dong-sheng Chen, et al. · Oral Oncology · 3
EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma
2020 · Shengzhuang Yang, Lijian Li, et al. · Journal of Cancer Research and Clinical Oncology · 3
A Novel Oncogenic RET Fusion Variant in Non–Small Cell Lung Cancer: RELCH-RET
2020 · Huachi Jiang, Mingzhe Xiao, et al. · Journal of Thoracic Oncology · 3
Works count: 64
Citation count: 494
H-index: 8
I10-index: 7
Year
Topic
Type